What are the hemoglobin targets when using aranesp?

Recommended Hemoglobin Targets for Aranesp

Aranesp (darbepoetin alfa) treats anemia in chronic kidney disease (CKD) patients on dialysis or not on dialysis, and in chemotherapy-induced anemia. The target hemoglobin (Hb) level is 10-11 g/dL. Do not exceed 11 g/dL to minimize risks like stroke, thrombosis, and death.[1][2]

Targets by Patient Group

• CKD patients on dialysis: Initiate Aranesp if Hb <10 g/dL. Titrate to maintain 10-11 g/dL. Reduce or stop dosing if Hb approaches 11 g/dL.[1]
  
• CKD patients not on dialysis: Same 10-11 g/dL range. Use lowest dose to avoid exceeding 11 g/dL, with slower titration due to less frequent monitoring.[1]
  
• Chemotherapy-induced anemia: Target 10-12 g/dL in some guidelines, but FDA labeling caps at 11 g/dL maximum, aligning with CKD targets. Reserve for Hb ≤10 g/dL when chemotherapy causes anemia.[1][2]
  
  

How Dosing Achieves Targets

Start with 0.45 mcg/kg IV/SC weekly for dialysis CKD, or 0.75 mcg/kg weekly/biweekly for non-dialysis. Adjust by 25% every 4 weeks based on Hb trends: increase if rising <1 g/dL over 4 weeks or <10 g/dL; decrease if >11 g/dL or rising >1 g/dL in 2 weeks. Monitor Hb every 2-4 weeks.[1]

Risks of Higher Targets

Trials like CHOIR (Hb target 13.5 vs 11.3 g/dL) and TREAT (13.5 vs 9 g/dL) showed higher targets increase stroke, hypertension, and vascular events. Normalizing Hb to 12-16 g/dL raises mortality risk, leading to the strict 10-11 g/dL cap.[1][3]

Monitoring and Adjustments

Check Hb twice weekly until stable, then every 2-4 weeks. Hold Aranesp if Hb >11 g/dL; restart at 25-50% lower dose when <10 g/dL. Use iron therapy if ferritin <100 ng/mL or TSAT <20% before or during treatment.[1]

[1]: Aranesp Prescribing Information (Amgen)
[2]: FDA Labeling for Aranesp
[3]: NKF-KDOQI Anemia Guidelines